STAT January 6, 2025
Adam Feuerstein

Readouts are coming from Ultragenyx, Akero Therapeutics, and Incyte

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
PBM Private Labeling Boosts Biosimilars, Raises Concerns
Q&A: How can drug repurposing lower drug costs and improve care?
BC researchers receive $49M for genomics projects

Share This Article